IDEAYA与施维雅在ASCO公布Darovasertib联合疗法一线治疗HLA-A2:01阴性转移性葡萄膜黑色素瘤的2/3期关键试验完整数据

美股速递
Jun 01

IDEAYA Biosciences与合作伙伴施维雅于美国临床肿瘤学会年会的一场最新突破性口头报告中,公布了其关键性2/3期OPTIMUM-02试验的完整数据。该试验评估了Darovasertib联合疗法,作为一线治疗方案,用于HLA-A2:01阴性转移性葡萄膜黑色素瘤患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10